Brean Capital Equities research analysts increased their price objective on NuVasive shares from $53 to $55 in a research note, according to a Dakota Financial News report.
↧
Brean Capital Equities research analysts increased their price objective on NuVasive shares from $53 to $55 in a research note, according to a Dakota Financial News report.